Jinhe Biotechnology CO., LTD. (002688.SZ)

CNY 4.85

(4.08%)

Market Cap (In CNY)

3.63 Billion

Revenue (In CNY)

2.17 Billion

Net Income (In CNY)

86.45 Million

Avg. Volume

5.91 Million

Currency
CNY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
2.91-5.2
PE
-
EPS
-
Beta Value
0.405
ISIN
CNE100001HK7
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Changxian Xie
Employee Count
-
Website
https://www.jinhe.com.cn
Ipo Date
2012-07-13
Details
Jinhe Biotechnology CO., LTD. produces and sells veterinary medicines in China. The company offers chlortetracycline feed grade, an antimicrobial drug for the inhibition and treatment of white dysentery, enteritis, pneumonia, typhoid, paratyphoid, cholera, etc. in poultry and livestock; and chlortetracycline hydrochloride for the inhibition and treatment of pullorum disease, typhoid, and swine enteritis, as well as bacterial diseases, including paratyphoid and cholera. It also exports its products to the United States, South-east Asia, Latin America, Europe, etc. The company was founded in 1990 and is based in Dalian, China.